Anaconda Biomed, a medical technology company developing a next-generation thrombectomy system for the treatment of ischemic stroke, has announced the completion of initial patient cases in a first-in-human study at the Vall d'Hebron Barcelona Hospital.
This 125-patient, prospective, multi-center study will assess system safety and reperfusion measured using the modified treatment in cerebral infarction (mTICI) score. Study data will be used to support a regulatory submission to the US Food and Drug Administration.
“Our goal is to minimize the risk of death and disability following a stroke, and we look forward to using the study results to move us closer to bringing this new alternative to patients” explains Dr Francois Salmon, CEO of Anaconda.
Dr Marc Ribó, Assistant Professor Stroke Unit at Vall d’Hebron, performed the study’s first case.
Photo: Ofir Arad and Marc Ribó, co-founders of Anaconda - © Anaconda Biomed
La mejor actitud que podemos adoptar es la de trat...
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Un artículo publicado en Alzheimer’s & Dementia: The Journal of the...
